The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Subgroup benefits identified in RELATIVITY-104 for advanced non-small cell lung cancer
Nicolas Girard, MD, Institut Curie, Paris, France, discusses findings from the Phase II RELATIVITY-104 trial (NCT04623775), which compared platinum doublet chemotherapy plus nivolumab to a combination of platinum doublet chemotherapy, nivolumab, and relatlimab in metastatic non-small cell lung cancer (NSCLC). While the overall study did not meet statistical significance for the primary endpoint in the intent-to-treat population, a subgroup analysis showed promising results in patients with non-squamous NSCLC with PD-L1 expression ≥1%. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
